The Global Influenza Market

  • November 2013
  • -
  • BCC Research
  • -
  • 196 pages

STUDY GOALS AND OBJECTIVES

This BCC Research report, The Global Influenza Market is an update to the latest edition of the BCC Research report published in 2009. This report provides an overview of products currently in the marketplace and a detailed analysis of market position and competitive environments. The study includes information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers. There is a special emphasis on U.S. and European markets.

REASONS FOR DOING THE STUDY

Annually, up to a half-million people die of influenza and, with the threat of a pandemic in any given year, government agencies and disease prevention organizations are devoted to gaining control of the situation. The 2009 pandemic generated attention to surveillance measures, pandemic preparedness, vaccine production and antiviral control. It also revealed issues with laboratory capacity and the benefits of rapid testing in a pandemic situation.

Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next five years will continue to display support and funding for many research and development (R&D) programs, product development, and pandemic prevention and/or control by worldwide governments, organizations, and health professionals.

SCOPE OF REPORT

This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.

METHODOLOGY AND INFORMATION SOURCES

The information for this BCC report was obtained through primary and secondary data collection methods. Primary methods included interviews with key representatives in the industry: product development managers, clinical specialists, government departments and other key representatives involved in the influenza industry. Secondary methods included published literature, investment reports, company literature and various business journals that have emphasis on influenza products, technology and related information.

Market data for this report pertains to the worldwide market, with specific U.S. data included. All information is displayed using U.S. dollars at the manufacturers’ level. The base year of the report is 2013, with historical data provided for the years 2007 through 2012, and forecast data provided for 2018. Historical, base year and forecast data are provided for each market segment of the report. Compound annual growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D, current product growth, and government intervention and stockpiling trends. Competitor market share estimates are provided for each market segment for the years 2010, 2011 and 2012 and the 2013 base year.

INTENDED AUDIENCE

This BCC study provides a comprehensive analysis of the global influenza market. This study will provide the reader with a heightened awareness of the overall market and factors affecting current and future growth. The study is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants and anyone in the medical field with an interest in the influenza market. The projections, forecasts, and trend analyses found in this report provide readers with the necessary data and information for careful decision making.

ANALYST CREDENTIALS

Melissa Elder is an experienced healthcare market analyst, specializing in prescription and over-the-counter pharmaceuticals, medical devices and emerging healthcare technologies. Ms. Elder has over 20 years of experience in the healthcare industry, specializing in market research for the past 15 years. This experience has given her substantial insight into pharmaceutical market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets.

REPORT HIGHLIGHTS

The global influenza market will grow from nearly $3.8 billion in 2012 to $4 billion in 2013. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018.

This report provides:
• An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 and 2018.
• Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
• Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
• Comprehensive company profiles of major players.

Table Of Contents

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
METHODOLOGY AND INFORMATION SOURCES 2
INTENDED AUDIENCE 3
RELATED BCC RESEARCH STUDIES 3
ANALYST CREDENTIALS 3
BCC RESEARCH ON-LINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY 6
SUMMARY TABLE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT,
THROUGH 2018 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT,
2007-2018 ($ MILLIONS) 7

CHAPTER 3 INDUSTRY OVERVIEW 9

OVERVIEW 9
HISTORY OF THE MARKET 9
EPIDEMICS/PANDEMICS 9
Spanish Influenza 1918-1919 9
Hong Kong Influenza 1968 10
Asian Influenza 1957 10
Swine Flu 1976 10
Russian Influenza 1977 10
Avian Flu 1961, 1997, 2003-2009/2010 (Sporadic) 10
Novel Influenza H1N1 2009 11
TABLE 1 DISTRIBUTION OF FATAL CASES OF 2009-2010 H1N1 PANDEMIC BY WHO
REGION 11
Novel Influenza H7N9 12
TABLE 2 CUMULATIVE NUMBER OF CONFIRMED CASES AND DEATHS OF H7N9 BY
MONTH, AS OF AUGUST 2013 12
TABLE 3 NUMBER OF CONFIRMED CASES OF H7N9 BY REGION, AS OF AUGUST
2013 12
VIRUS MUTATIONS 13
TYPES OF INFLUENZA 13
Influenza Type A 13
Influenza A H5 14
Influenza A H7 14
Influenza A H9 14
Influenza A H1 14
Influenza A H10 14
Influenza Type B 14
Influenza Type C 14
WORLD ACTIVITY OF INFLUENZA VIRUSES 14
TABLE 4 WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES AFFECTED BY TYPE 15
THE WORLD HEALTH ORGANIZATION (WHO) AND THE CENTERS FOR DISEASE
CONTROL AND PREVENTION (CDC): INFLUENZA RESPONSE 17
WORLD HEALTH ORGANIZATION 17
CENTERS FOR DISEASE CONTROL AND PREVENTION 18
U.S. VIRAL SURVEILLANCE 19
TABLE 5 VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS TYPE, 2005-2011
FLU SEASONS (%) 19
FIGURE 1 VIRAL SURVEILLANCE TREND FOR INFLUENZA VIRUS TYPE, 2005-2011
FLU SEASONS (%) 19
FDA'S VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY
COMMITTEE AND VACCINE COMPOSITION 20
TABLE 6 INFLUENZA VIRUS RECOMMENDATIONS, U.S. INFLUENZA SEASONS,
2003-2014 20
VACCINE RECOMMENDATIONS 21
TABLE 7 THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED) 22
TABLE 8 CDC INFLUENZA VACCINE RECOMMENDATIONS 23
FIGURE 2 RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF
PERSONS WHO REPORT ALLERGY TO EGGS: ADVISORY COMMITTEE ON
IMMUNIZATION PRACTICES, U.S., 2013-2014 INFLUENZA SEASON
24
UNIVERSAL VACCINE 24
POPULATION DEMOGRAPHICS AND INFLUENZA INCIDENCE/MORTALITY 25
GLOBAL DEMOGRAPHICS 25
TABLE 9 GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP
AND SELECTED YEARS, THROUGH 2030 (MILLIONS) 26
FIGURE 3 GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS,
2000-2030 (MILLIONS) 26
TABLE 10 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015
(MILLIONS) 27
FIGURE 4 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED
2015 (MILLIONS) 28
GLOBAL LIFE EXPECTANCY 28
TABLE 11 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND
2010 (YEARS) 29
FIGURE 5 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND
2010 (YEARS) 29
INFLUENZA INCIDENCE AND MORTALITY 30
TABLE 12 WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON 2012 DATA AND
POPULATION 30
TABLE 13 U.S. VIRAL STATISTICS ESTIMATED ON 2012 DATA AND POPULATION 30
TABLE 14 IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS
AND DEATHS BY AGE GROUP APRIL 2009-APRIL 2010 31

CHAPTER 4 ISSUES AFFECTING THE MARKET 34

H1N1 OUTBREAK 2009 (SWINE FLU) 34
RAPID DIAGNOSTICS 34
Pandemic Testing 34
Seasonal Influenza Tests 35
AVIAN FLU 35
U.S. GOVERNMENT INTERVENTION 35
TABLE 15 COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD
IMPORT RESTRICTIONS 36
AVIAN FLU SURVEILLANCE 36
TABLE 16 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS
(NUMBER) 37
FIGURE 6 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS
(NUMBER) 38
Avian Flu (H5N1) Outbreaks in Animals 38
TABLE 17 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE,
2003 TO AUGUST 19, 2013 (NUMBER) 39
FIGURE 7 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE,
BY REGION, 2003 TO AUGUST 19, 2013 (NUMBER) 40
The WHO and Containment for Pandemic Influenza 41
TABLE 18 APPROVED WHO INFLUENZA CENTERS BY REGION 42
FIGURE 8 NUMBER OF APPROVED WHO INFLUENZA CENTERS BY WHO BROAD
REGION (%) 62
INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS 63
PRE-PANDEMIC VACCINATION 64
TABLE 19 TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON
POPULATION DEMANDS OF SELECTED COUNTRIES (MILLIONS) 64
Biomedical Advanced Research and Development Authority (BARDA) 64
ANTIVIRAL RESISTANCE 65
RECREATED VIRUSES 66
HHS CONTRACTS FOR RELATED TECHNOLOGIES 66
TABLE 20 HHS CONTRACTS AWARDED FOR RESEARCH AND DEVELOPMENT OF
RECOMBINANT INFLUENZA VACCINE 67
MARKET FAILURE TO MATERIALIZE 67
MEDIA COVERAGE AND VACCINATIONS 68
EPIDEMIC/PANDEMIC THREAT 68
TABLE 21 ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA FOR 2013 SEVERE
OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU
INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS)
69
PANDEMIC PREPAREDNESS PLANS 71
TABLE 22 ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA
PANDEMIC PREPAREDNESS PLAN 71
THE UNITED STATES 72
JAPAN 73
TABLE 23 OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA
PANDEMIC PREPAREDNESS 74
CHINA 75
TABLE 24 CHINA INFLUENZA PANDEMIC WARNING LEVELS 76
BRAZIL 76
TABLE 25 BRAZIL INFLUENZA PANDEMIC WARNING LEVELS AND ACTION 76
UNITED KINGDOM 77
WORLD INFLUENZA IMPACT 78
IMPACT OF SEASONAL FLU ON THE U.S. ECONOMY 78
TABLE 26 NATIONWIDE INFLUENZA-RELATED COSTS AND DISTRIBUTIONS BY AGE
GROUP, BY RISK AND BY HEALTH OUTCOME, ALL ADOPTED FROM MOLINARI ET
AL., 2007
78
HOSPITAL BED UTILIZATION DURING INFLUENZA PANDEMIC 80
TABLE 27 ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE
BEDS BY SELECTED COUNTRY, 2013 ESTIMATES 80
FIGURE 9 ESTIMATED NUMBER OF AVAILABLE BEDS BY SELECTED COUNTRY, 2013
ESTIMATES (NUMBER) 81
ANTIVIRAL RESISTANCE 81

CHAPTER 5 PATENT ANALYSIS 84

OVERVIEW 84
INFLUENZA PATENTS BY PATENT NUMBER 84
TABLE 28 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS) 84
FIGURE 10 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF
PATENTS) 84
TABLE 29 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT
NUMBER 85
TABLE 30 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR 89
BRISTOL-MYERS SQUIBB 90
CRUCELL HOLLAND 90
MEDIMMUNE 91
NEW YORK UNIVERSITY 91
NOVARTIS 92
NOVAVAX 92
UNIVERSITY OF PITTSBURGH 92
WISCONSIN ALUMNI RESEARCH FOUNDATION 93
YEDA RESEARCH AND DEVELOPMENT 93

CHAPTER 6 INFLUENZA VACCINES 95

OVERVIEW 95
HISTORY OF VACCINE MANUFACTURER PARTICIPATION IN THE U.S. 95
TABLE 31 VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2014
INFLUENZA YEAR 95
CURRENT VACCINES 97
BAXTER INTERNATIONAL 97
CSL BIOTHERAPIES 97
GLAXOSMITHKLINE 97
MEDIMMUNE 98
NOVARTIS 98
PROTEIN SCIENCES CORP. 99
SANOFI PASTEUR 99
SOLVAY PHARMACEUTICALS 99
TABLE 32 EXAMPLES OF MARKETED INFLUENZA VACCINE PRODUCTS 100
SEASONAL 2008-2009 VACCINE APPROVALS BY FDA 100
TABLE 33 SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2013-2014
INFLUENZA SEASON, BASED ON ADULT DOSAGE 101
RECENT PRE-PANDEMIC AND PANDEMIC APPROVALS 101
VACCINE DEVELOPMENTS 101
ALPHAVAX 101
ANTIGEN EXPRESS 101
BIONDVAX PHARMACEUTICALS 102
CRUCELL 102
CURELAB 102
GENEREX BIOTECHNOLOGY 102
IBIO, INC. 102
INOVIO PHARMACEUTICALS 102
MEDICAGO 103
MEDIMMUNE 103
NANOBIO CORP. 103
NANOTHERAPEUTICS, INC. 103
NANOVIRICIDES, INC. 104
NEXBIO, INC. 104
NOVARTIS VACCINES 104
NOVAVAX, INC. 104
PAXVAX CORP. 105
PROTEIN SCIENCES CORP. 105
SANOFI PASTEUR 105
VAXART, INC. 105
VAXIN, INC. 105
VAXINNATE 106
TABLE 34 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS 106
FIGURE 11 NUMBER OF INFLUENZA RESEARCH AND DEVELOPMENT PROJECTS BY
PROGRESS 108
RECENT INDUSTRY NEWS 109
THE GLOBAL INFLUENZA VACCINE MARKET 109
TABLE 35 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 110
FIGURE 12 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
2010-2018 ($ MILLIONS) 110
SEASONAL VS. PANDEMIC SALES 111
FIGURE 13 GLOBAL REVENUES FOR INFLUENZA VACCINES BY SEASONAL VS.
PANDEMIC SUPPLY ORDERS, 2007-2013 ($ MILLIONS) 111
REGIONAL MARKET SUMMARY 111
TABLE 36 GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018
($ MILLIONS) 112
FIGURE 14 GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018
($ MILLIONS) 112
FIGURE 15 DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES BY REGION,
2013 (%) 112
THE U.S. INFLUENZA VACCINE MARKET 113
TABLE 37 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
2007-2018 ($ MILLIONS) 114
FIGURE 16 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
2010-2018 ($ MILLIONS) 115
TABLE 38 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY INFLUENZA SEASON,
2005-2013 115
FIGURE 17 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2013 115
TABLE 39 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY
MANUFACTURER, 2012-2013 SEASON (UNITS PER MILLION) 116
FIGURE 18 SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S.
BY MANUFACTURER, 2012-2013 SEASON (%) 116
THE EUROPEAN INFLUENZA VACCINE MARKET 116
TABLE 40 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 117
FIGURE 19 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
2010-2018 ($ MILLIONS) 117
COMPETITOR ANALYSIS 118
TABLE 41 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON
GLOBAL REVENUES, 2010-2013 (%) 118
FIGURE 20 LEADING PARTICIPANTS’ SHARE OF INFLUENZA VACCINES BASED ON
GLOBAL REVENUES, 2010 (%) 119
FIGURE 21 LEADING PARTICIPANTS’ SHARE OF INFLUENZA BASED ON GLOBAL
REVENUES, 2011 (%) 119
FIGURE 22 LEADING PARTICIPANTS’ SHARE OF INFLUENZA VACCINES BASED ON
GLOBAL REVENUES, 2012 (%) 119
FIGURE 23 LEADING PARTICIPANTS’ SHARE OF INFLUENZA VACCINES BASED ON
GLOBAL REVENUES, 2013 (%) 120

CHAPTER 7 INFLUENZA THERAPIES 122

OVERVIEW 122
CURRENT THERAPIES 122
GLAXOSMITHKLINE 122
ROCHE 122
OTHERS 122
TABLE 42 MARKETED THERAPIES, THROUGH 2013 123
SEASONAL DOSAGE RECOMMENDATIONS FOR ANTIVIRALS 123
TABLE 43 RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL
MEDICATIONS BY ANTIVIRAL AGENT AND AGE: U.S. 123
GENERIC AVAILABILITY 125
TABLE 44 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS 126
INFLUENZA BIOLOGICAL DEVELOPMENTS 126
ADAMAS PHARMACEUTICALS 126
AMARILLO BIOSCIENCES, INC. 127
BIOCRYST PHARMACEUTICALS 127
BIOTA HOLDINGS 127
CRUCELL 127
FUNCTIONAL GENETICS, INC. 127
GLAXOSMITHKLINE 128
HEMISPHERX BIOPHARMA 128
ROMARK LABORATORIES 128
SAREPTA THERAPEUTICS 128
THERACLONE SCIENCES 128
TOYAMA CHEMICAL 129
TABLE 45 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS 129
THE GLOBAL INFLUENZA THERAPEUTICS MARKET 130
TABLE 46 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 131
FIGURE 24 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY
MANUFACTURER, 2010-2018 ($ MILLIONS) 131
REGIONAL MARKET SUMMARY 131
TABLE 47 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION,
THROUGH 2018 ($ MILLIONS) 132
FIGURE 25 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION,
2010-2018 ($ MILLIONS) 132
FIGURE 26 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES BY
REGION, 2013 (%) 132
Influenza Therapeutics Market in The U.S. 133
TABLE 48 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 134
FIGURE 27 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
2010-2018 ($ MILLIONS) 134
Influenza Therapeutics Market In Europe 134
TABLE 49 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 135
FIGURE 28 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY
MANUFACTURER, 2010-2018 ($ MILLIONS) 135
COMPETITOR ANALYSIS 135
TABLE 50 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON
GLOBAL REVENUES, 2010-2013 (%) 136
FIGURE 29 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON
GLOBAL REVENUES, 2010 (%) 136
FIGURE 30 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES,
2011 (%) 137
FIGURE 31 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES,
2012 (%) 137
FIGURE 32 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES,
2013 (%) 137

CHAPTER 8 INFLUENZA VACCINE/THERAPEUTICS MARKET ANALYSIS 140

TABLE 51 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION,
THROUGH 2018 ($ MILLIONS) 140
FIGURE 33 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION,
2010-2018 ($ MILLIONS) 141
FIGURE 34 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES
SALES BY REGION, 2013 (%) 141
TABLE 52 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT
TYPE, THROUGH 2018 ($ MILLIONS) 142
FIGURE 35 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY
PRODUCT TYPE, 2010-2018 ($ MILLIONS) 143
FIGURE 36 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES
BY PRODUCT TYPE, 2013 (%) 143
CLINICAL TRIALS 144
TABLE 53 CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY
SELECTED COUNTRY AND TRIAL STATUS 144
FIGURE 37 CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY
SELECTED COUNTRY AND TRIAL STATUS 144

CHAPTER 9 INFLUENZA DIAGNOSTICS 147

OVERVIEW 147
TABLE 54 INFLUENZA DIAGNOSTIC TABLE 147
TEST DESCRIPTIONS2 148
Viral Culture 148
Rapid Influenza Diagnostic Tests 148
TABLE 55 CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA
PREVALENCE IS HIGH (%) 149
TABLE 56 CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA
PREVALENCE IS LOW (%) 149
Serologic Testing 150
PRODUCT DESCRIPTION 150
Conventional Laboratory Tests 150
Applied Biosystems 150
Qiagen, Inc. 150
Rapid Testing 150
3M and Response Biomedical Corp. 151
Alere 151
Becton Dickinson 151
BTNX, Inc. 152
Cepheid 152
Hologic, Inc. 152
Luminex Corp. 153
Meridian Biosciences, Inc. 153
OraSure Technologies 153
Quidel Corp. 153
Remel, Inc. (Thermo Scientific) 154
SA Scientific, Ltd. 154
Sekisui Diagnostics 154
TABLE 57 SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH AUGUST 2013 154
TABLE 58 SELECTED RAPID INFLUENZA TESTS AVERAGE PRICE ($) 156
LABORATORY SERVICES 156
Associated Regional University Pathologists (ARUP) Laboratories 156
Bio-Reference Laboratories, Inc. 156
Laboratory Corp. of America 156
Pathology Associates Medical Laboratories 157
Quest Diagnostics 157
TABLE 59 PROVIDERS OF TEST SERVICES 157
RECENT INDUSTRY NEWS 157
MARKET ANALYSIS 158
TABLE 60 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH
2018 ($ MILLIONS) 158
FIGURE 38 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE,
2010-2018 ($ MILLIONS) 158
REGIONAL MARKET SUMMARY 159
TABLE 61 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION,
THROUGH 2018 ($ MILLIONS) 159
FIGURE 39 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION,
2010-2018 ($ MILLIONS) 159
FIGURE 40 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION,
2013 (%) 160
TABLE 62 NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA
INDICATIONS IN THE U.S., 2000-2013* 161
FIGURE 41 NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA
INDICATIONS IN THE U.S., 2000-2013* 161
COMPETITOR ANALYSIS 161
TABLE 63 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE,
BASED ON GLOBAL REVENUES, 2010-2013 ($) 162
FIGURE 42 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY
PERCENTAGE, BASED ON GLOBAL REVENUES, 2010 (%) 162
FIGURE 43 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY
PERCENTAGE, BASED ON GLOBAL REVENUES, 2011 (%) 162
FIGURE 44 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY
PERCENTAGE, BASED ON GLOBAL REVENUES, 2012 (%) 163
FIGURE 45 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY
PERCENTAGE, BASED ON GLOBAL REVENUES, 2013 (%) 163

CHAPTER 10 INFLUENZA MARKET SUMMARY 166

TOTAL MARKET ANALYSIS 166
TABLE 64 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT,
THROUGH 2018 ($ MILLIONS) 166
FIGURE 46 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT,
2010-2018 ($ MILLIONS) 166
FIGURE 47 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT,
2013 (%) 167
REGIONAL MARKET SUMMARY 168
TABLE 65 GLOBAL INFLUENZA MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 168
FIGURE 48 GLOBAL INFLUENZA MARKET BY REGION, 2010-2018 ($ MILLIONS) 169
FIGURE 49 DISTRIBUTION OF GLOBAL INFLUENZA MARKET BY REGION, 2013 (%) 169
OVERVIEW OF INFLUENZA MARKET TRENDS 170
TABLE 66 INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS 170
TABLE 67 INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS 170
TABLE 68 INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS 170
INDUSTRY PARTICIPANTS 171
TABLE 69 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT, INDUSTRY
PARTICIPANTS BY TYPE 171

CHAPTER 11 COMPANY PROFILES 173

SIGNIFICANT COMPANY ACQUISITIONS 173
ABBOTT LABORATORIES 173
TABLE 70 ABBOTT'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 174
FIGURE 50 ABBOTT’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 174
ALERE INC. 174
TABLE 71 ALERE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 175
FIGURE 51 ALERE’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 175
ASTRAZENECA/MEDIMMUNE 175
TABLE 72 ASTRAZENECA'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 176
FIGURE 52 ASTRAZENECA’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 176
BECTON DICKINSON AND COMPANY 177
TABLE 73 BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 178
FIGURE 53 BECTON DICKINSON’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 178
CSL LIMITED 178
TABLE 74 CSL LIMITED'S COMPANY REVENUES, 2009-2013* ($ MILLIONS) 179
FIGURE 54 CSL LIMITED’S COMPANY REVENUES, 2009-2013* ($ MILLIONS) 179
GLAXOSMITHKLINE PLC 180
TABLE 75 GLAXOSMITHKLINE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 180
FIGURE 55 GLAXOSMITHKLINE’S COMPANY REVENUES 2009-2012 ($ MILLIONS) 181
MITSUBISHI TANABE PHARMA CORP. 181
TABLE 76 MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 182
FIGURE 56 MITSUBISHI TANABE’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 182
NOVARTIS AG 182
TABLE 77 NOVARTIS' COMPANY REVENUES, 2009-2012 ($ MILLIONS) 183
FIGURE 57 NOVARTIS’ COMPANY REVENUES, 2009-2012 ($ MILLIONS) 183
QUIDEL CORP. 183
TABLE 78 QUIDEL'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 184
FIGURE 58 QUIDEL’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 184
ROCHE LTD. 185
TABLE 79 ROCHE GROUP'S REVENUES, 2009-2012 ($ MILLIONS) 185
FIGURE 59 ROCHE GROUP’S REVENUES, 2009-2012 ($ MILLIONS) 185
SANOFI/SANOFI PASTEUR 186
TABLE 80 SANOFI'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 187
FIGURE 60 SANOFI’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 188

CHAPTER 12 APPENDICES 190

APPENDIX I 190
MANUFACTURERS AND DEVELOPERS 190
APPENDIX II 202
MENTIONED UNIVERSITIES AND SCHOOLS 202
APPENDIX III 204
GLOSSARY OF TERMS3 204
APPENDIX IV 206
LIST OF ACRONYMS 206



LIST OF TABLES

SUMMARY TABLE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT,
THROUGH 2018 ($ MILLIONS) 7
TABLE 1 DISTRIBUTION OF FATAL CASES OF 2009-2010 H1N1 PANDEMIC BY WHO
REGION 11
TABLE 2 CUMULATIVE NUMBER OF CONFIRMED CASES AND DEATHS OF H7N9 BY
MONTH, AS OF AUGUST 2013 12
TABLE 3 NUMBER OF CONFIRMED CASES OF H7N9 BY REGION, AS OF AUGUST 2013 12
TABLE 4 WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES AFFECTED BY TYPE 15
TABLE 5 VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS TYPE, 2005-2011
FLU SEASONS (%) 19
TABLE 6 INFLUENZA VIRUS RECOMMENDATIONS, U.S. INFLUENZA SEASONS,
2003-2014 20
TABLE 7 THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED) 22
TABLE 8 CDC INFLUENZA VACCINE RECOMMENDATIONS 23
TABLE 9 GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP
AND SELECTED YEARS, THROUGH 2030 (MILLIONS) 26
TABLE 10 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS) 27
TABLE 11 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND
2010 (YEARS) 29
TABLE 12 WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON 2012 DATA AND
POPULATION 30
TABLE 13 U.S. VIRAL STATISTICS ESTIMATED ON 2012 DATA AND POPULATION 30
TABLE 14 IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND
DEATHS BY AGE GROUP APRIL 2009-APRIL 2010 31
TABLE 15 COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD
IMPORT RESTRICTIONS 36
TABLE 16 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS
(NUMBER) 37
TABLE 17 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE,
2003 TO AUGUST 19, 2013 (NUMBER) 39
TABLE 18 APPROVED WHO INFLUENZA CENTERS BY REGION 42
TABLE 19 TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON
POPULATION DEMANDS OF SELECTED COUNTRIES (MILLIONS) 64
TABLE 20 HHS CONTRACTS AWARDED FOR RESEARCH AND DEVELOPMENT OF
RECOMBINANT INFLUENZA VACCINE 67
TABLE 21 ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA FOR 2013 SEVERE
OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU
INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS)
69
TABLE 22 ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA
PANDEMIC PREPAREDNESS PLAN 71
TABLE 23 OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA
PANDEMIC PREPAREDNESS 74
TABLE 24 CHINA INFLUENZA PANDEMIC WARNING LEVELS 76
TABLE 25 BRAZIL INFLUENZA PANDEMIC WARNING LEVELS AND ACTION 76
TABLE 26 NATIONWIDE INFLUENZA-RELATED COSTS AND DISTRIBUTIONS BY AGE
GROUP, BY RISK AND BY HEALTH OUTCOME, ALL ADOPTED FROM MOLINARI ET AL.,
2007
78
TABLE 27 ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE
BEDS BY SELECTED COUNTRY, 2013 ESTIMATES 80
TABLE 28 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS) 84
TABLE 29 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT NUMBER 85
TABLE 30 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR 89
TABLE 31 VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2014
INFLUENZA YEAR 95
TABLE 32 EXAMPLES OF MARKETED INFLUENZA VACCINE PRODUCTS 100
TABLE 33 SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2013-2014
INFLUENZA SEASON, BASED ON ADULT DOSAGE 101
TABLE 34 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS 106
TABLE 35 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 110
TABLE 36 GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 ($
MILLIONS) 112
TABLE 37 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
2007-2018 ($ MILLIONS) 114
TABLE 38 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY INFLUENZA SEASON,
2005-2013 115
TABLE 39 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY
MANUFACTURER, 2012-2013 SEASON (UNITS PER MILLION) 116
TABLE 40 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 117
TABLE 41 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON
GLOBAL REVENUES, 2010-2013 (%) 118
TABLE 42 MARKETED THERAPIES, THROUGH 2013 123
TABLE 43 RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL
MEDICATIONS BY ANTIVIRAL AGENT AND AGE: U.S. 123
TABLE 44 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS 126
TABLE 45 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS 129
TABLE 46 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 131
TABLE 47 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION,
THROUGH 2018 ($ MILLIONS) 132
TABLE 48 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 134
TABLE 49 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
THROUGH 2018 ($ MILLIONS) 135
TABLE 50 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON
GLOBAL REVENUES, 2010-2013 (%) 136
TABLE 51 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION,
THROUGH 2018 ($ MILLIONS) 140
TABLE 52 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT
TYPE, THROUGH 2018 ($ MILLIONS) 142
TABLE 53 CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY
SELECTED COUNTRY AND TRIAL STATUS 144
TABLE 54 INFLUENZA DIAGNOSTIC TABLE 147
TABLE 55 CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA
PREVALENCE IS HIGH (%) 149
TABLE 56 CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA
PREVALENCE IS LOW (%) 149
TABLE 57 SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH AUGUST 2013 154
TABLE 58 SELECTED RAPID INFLUENZA TESTS AVERAGE PRICE ($) 156
TABLE 59 PROVIDERS OF TEST SERVICES 157
TABLE 60 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH
2018 ($ MILLIONS) 158
TABLE 61 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, THROUGH
2018 ($ MILLIONS) 159
TABLE 62 NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA
INDICATIONS IN THE U.S., 2000-2013* 161
TABLE 63 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE,
BASED ON GLOBAL REVENUES, 2010-2013 ($) 162
TABLE 64 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, THROUGH
2018 ($ MILLIONS) 166
TABLE 65 GLOBAL INFLUENZA MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 168
TABLE 66 INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS 170
TABLE 67 INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS 170
TABLE 68 INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS 170
TABLE 69 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT, INDUSTRY
PARTICIPANTS BY TYPE 171
TABLE 70 ABBOTT'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 174
TABLE 71 ALERE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 175
TABLE 72 ASTRAZENECA'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 176
TABLE 73 BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 178
TABLE 74 CSL LIMITED'S COMPANY REVENUES, 2009-2013* ($ MILLIONS) 179
TABLE 75 GLAXOSMITHKLINE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 180
TABLE 76 MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 182
TABLE 77 NOVARTIS' COMPANY REVENUES, 2009-2012 ($ MILLIONS) 183
TABLE 78 QUIDEL'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 184
TABLE 79 ROCHE GROUP'S REVENUES, 2009-2012 ($ MILLIONS) 185
TABLE 80 SANOFI'S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 187



LIST OF FIGURES

SUMMARY FIGURE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT,
2007-2018 ($ MILLIONS) 7
FIGURE 1 VIRAL SURVEILLANCE TREND FOR INFLUENZA VIRUS TYPE, 2005-2011 FLU
SEASONS (%) 19
FIGURE 2 RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS
WHO REPORT ALLERGY TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION
PRACTICES, U.S., 2013-2014 INFLUENZA SEASON
24
FIGURE 3 GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS,
2000-2030 (MILLIONS) 26
FIGURE 4 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED
2015 (MILLIONS) 28
FIGURE 5 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND
2010 (YEARS) 29
FIGURE 6 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS
(NUMBER) 38
FIGURE 7 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE,
BY REGION, 2003 TO AUGUST 19, 2013 (NUMBER) 40
FIGURE 8 NUMBER OF APPROVED WHO INFLUENZA CENTERS BY WHO BROAD
REGION (%) 62
FIGURE 9 ESTIMATED NUMBER OF AVAILABLE BEDS BY SELECTED COUNTRY, 2013
ESTIMATES (NUMBER) 81
FIGURE 10 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS) 84
FIGURE 11 NUMBER OF INFLUENZA RESEARCH AND DEVELOPMENT PROJECTS BY
PROGRESS 108
FIGURE 12 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
2010-2018 ($ MILLIONS) 110
FIGURE 13 GLOBAL REVENUES FOR INFLUENZA VACCINES BY SEASONAL VS.
PANDEMIC SUPPLY ORDERS, 2007-2013 ($ MILLIONS) 111
FIGURE 14 GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018
($ MILLIONS) 112
FIGURE 15 DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES BY REGION, 2013
(%) 112
FIGURE 16 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
2010-2018 ($ MILLIONS) 115
FIGURE 17 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2013 115
FIGURE 18 SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY
MANUFACTURER, 2012-2013 SEASON (%) 116
FIGURE 19 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER,
2010-2018 ($ MILLIONS) 117
FIGURE 20 LEADING PARTICIPANTS’ SHARE OF INFLUENZA VACCINES BASED ON
GLOBAL REVENUES, 2010 (%) 119
FIGURE 21 LEADING PARTICIPANTS’ SHARE OF INFLUENZA BASED ON GLOBAL
REVENUES, 2011 (%) 119
FIGURE 22 LEADING PARTICIPANTS’ SHARE OF INFLUENZA VACCINES BASED ON
GLOBAL REVENUES, 2012 (%) 119
FIGURE 23 LEADING PARTICIPANTS’ SHARE OF INFLUENZA VACCINES BASED ON
GLOBAL REVENUES, 2013 (%) 120
FIGURE 24 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
2010-2018 ($ MILLIONS) 131
FIGURE 25 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION,
2010-2018 ($ MILLIONS) 132
FIGURE 26 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES BY REGION,
2013 (%) 132
FIGURE 27 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
2010-2018 ($ MILLIONS) 134
FIGURE 28 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER,
2010-2018 ($ MILLIONS) 135
FIGURE 29 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON
GLOBAL REVENUES, 2010 (%) 136
FIGURE 30 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES,
2011 (%) 137
FIGURE 31 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES,
2012 (%) 137
FIGURE 32 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES,
2013 (%) 137
FIGURE 33 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION,
2010-2018 ($ MILLIONS) 141
FIGURE 34 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES
SALES BY REGION, 2013 (%) 141
FIGURE 35 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT
TYPE, 2010-2018 ($ MILLIONS) 143
FIGURE 36 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES BY
PRODUCT TYPE, 2013 (%) 143
FIGURE 37 CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY
SELECTED COUNTRY AND TRIAL STATUS 144
FIGURE 38 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2010-2018
($ MILLIONS) 158
FIGURE 39 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION,
2010-2018 ($ MILLIONS) 159
FIGURE 40 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION,
2013 (%) 160
FIGURE 41 NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA
INDICATIONS IN THE U.S., 2000-2013* 161
FIGURE 42 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE,
BASED ON GLOBAL REVENUES, 2010 (%) 162
FIGURE 43 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE,
BASED ON GLOBAL REVENUES, 2011 (%) 162
FIGURE 44 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE,
BASED ON GLOBAL REVENUES, 2012 (%) 163
FIGURE 45 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE,
BASED ON GLOBAL REVENUES, 2013 (%) 163
FIGURE 46 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT,
2010-2018 ($ MILLIONS) 166
FIGURE 47 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT,
2013 (%) 167
FIGURE 48 GLOBAL INFLUENZA MARKET BY REGION, 2010-2018 ($ MILLIONS) 169
FIGURE 49 DISTRIBUTION OF GLOBAL INFLUENZA MARKET BY REGION, 2013 (%) 169
FIGURE 50 ABBOTT’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 174
FIGURE 51 ALERE’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 175
FIGURE 52 ASTRAZENECA’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 176
FIGURE 53 BECTON DICKINSON’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 178
FIGURE 54 CSL LIMITED’S COMPANY REVENUES, 2009-2013* ($ MILLIONS) 179
FIGURE 55 GLAXOSMITHKLINE’S COMPANY REVENUES 2009-2012 ($ MILLIONS) 181
FIGURE 56 MITSUBISHI TANABE’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 182
FIGURE 57 NOVARTIS’ COMPANY REVENUES, 2009-2012 ($ MILLIONS) 183
FIGURE 58 QUIDEL’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 184
FIGURE 59 ROCHE GROUP’S REVENUES, 2009-2012 ($ MILLIONS) 185
FIGURE 60 SANOFI’S COMPANY REVENUES, 2009-2012 ($ MILLIONS) 188

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Sleep Aids : Technologies and Global Markets

Sleep Aids : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Research on the working of the human brain in relation to sleep is a fairly new area, with many new and novel theories. The discovery of new mechanisms and chemicals in the brain has provided expanding ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.